Home-based Whole Course Multimodal Prehabilitation Based on 5G + Artificial Intelligence Mobile Health

Prior treatment

• Within 6 months before enrollment, the patient had experienced cerebral hemorrhage, cerebral infarction, TIA, or suffered from central nervous system diseases or mental disorders, and was unable to cooperate in completing neoadjuvant therapy and prehabilitation

Other illness

• Presence of severe systemic infections (e.g., multiple organ dysfunction syndrome \[MODS\]) or active infectious diseases (e.g., tuberculosis)
• Emergency surgery is required due to complications of the tumor (e.g. bleeding, perforation, obstruction)
• Simultaneous tumors or other diseases requiring simultaneous surgery (excluding laparoscopic cholecystectomy)

Lab values

• Severe cardiac dysfunction (preoperative LVEF \< 30% or NYHA classification IV), severe liver dysfunction (Child-Pugh C grade), severe kidney dysfunction (preoperative CRRT was received), ASA grade IV or above; 6MWD ≤ 250 meters

Other

• Distant metastasis
• Patients who are participating in any other clinical trials (except observational, non-interventional clinical study)

• Aged 18 years or older
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
• Histologically confirmation of gastric or gastroesophageal junction (GEJ) adenocarcinoma. For GEJ carcinomas, eligibility is strictly confined to those presenting with Siewert type III tumors or Siewert type II tumors that do not mandate a concurrent thoracotomy
• Multidisciplinary team (MDT) referral for neoadjuvant chemotherapy prior to gastrectomy
• For female participants of childbearing potential, a negative serum pregnancy test must be confirmed within 7 days prior to the initial administration of neoadjuvant therapy
• Capacity to comprehend and voluntarily sign a written informed consent form
• Ability to use digital technology (e.g., smart phones, wearable devices) independently or with the assistance of family members